Morgan Stanley raised the firm’s price target on Humana (HUM) to $301 from $288 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Lawmakers seek to break up PBMs from health insurers, WSJ reports
- CEO killing, rage over insurance pushes UnitedHealth into crisis, Bloomberg says
- AT&T announces long-term targets, BlackRock acquires HPS: Morning Buzz
- Humana (HUM) Stock Falls on News of CFO Departure
- Insurers collected billions in premiums from Medicare for veterans, WSJ says